48
Participants
Start Date
August 31, 2011
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
Atrasentan
Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
Placebo
Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
Site Reference ID/Investigator# 55543, Flushing
Site Reference ID/Investigator# 64023, Albany
Site Reference ID/Investigator# 61742, Pittsburgh
Site Reference ID/Investigator# 54123, Bethlehem
Site Reference ID/Investigator# 68986, Augusta
Site Reference ID/Investigator# 56642, Hollywood
Site Reference ID/Investigator# 56924, Boynton Beach
Site Reference ID/Investigator# 54132, Chattanooga
Site Reference ID/Investigator# 58147, Willoughby Hills
Site Reference ID/Investigator# 68982, Pontiac
Site Reference ID/Investigator# 54164, Fargo
Site Reference ID/Investigator# 56644, Chicago
Site Reference ID/Investigator# 54129, Baton Rouge
Site Reference ID/Investigator# 54108, Dallas
Site Reference ID/Investigator# 54126, Greenville
Site Reference ID/Investigator# 54116, North Richland Hills
Site Reference ID/Investigator# 58153, Houston
Site Reference ID/Investigator# 54110, Houston
Site Reference ID/Investigator# 54121, Denver
Site Reference ID/Investigator# 58144, Phoenix
Site Reference ID/Investigator# 71034, Tempe
Site Reference ID/Investigator# 70173, Los Angeles
Site Reference ID/Investigator# 56927, Azusa
Site Reference ID/Investigator# 70793, Azusa
Site Reference ID/Investigator# 64027, Chula Vista
Site Reference ID/Investigator# 64026, La Mesa
Site Reference ID/Investigator# 54120, Concord
Site Reference ID/Investigator# 54173, Silverdale
AbbVie (prior sponsor, Abbott)
INDUSTRY